Summary
• Profusa, Inc. (PFSA) shares rise 9% in pre-market trading, reaching $0.1657 due to increased interest in upcoming clinical data presentation.
• The company will present data on Lumee™ for peripheral artery disease at LINC 2026, scheduled for January 28, 2026.
• Despite recent declines in stock performance, heightened trading volume indicates renewed investor optimism ahead of the presentation.
Profusa, Inc. (PFSA) is seeing a notable pre-market rally, currently priced at $0.1657, reflecting an increase of 9% from its last close of $0.1525. This move comes amid heightened interest following the company’s recent announcement regarding its involvement in a significant clinical data presentation.
Anticipation Builds for Clinical Data Presentation
Profusa recently revealed that it will present clinical data from a U.S.-based study evaluating Lumee™ in patients with peripheral artery disease (PAD) at the Leipzig Interventional Course (LINC) 2026. Scheduled for January 28, 2026, this presentation aims to discuss insights into tissue oxygen monitoring, signaling the company’s commitment to advancing its digital health technologies.
The upcoming event is set to take place from January 27-30, 2026, in Leipzig, Germany, which has generated investor optimism surrounding the company’s innovative monitoring solutions.
Market Sentiment and Trading Performance
The stock has exhibited some volatility, with a quarterly performance decline of 59.3% and a monthly decrease of 24.9%. Yet, the current pre-market surge suggests renewed interest, as average trading volumes stand at approximately 9.3 million for the past 10 days, surpassing the 3-month average of 7.8 million.
The relative strength index (RSI) is currently at 37.67, indicating that while the stock may still be in a downward trend, recent trading activity is awakening bulls. The 20-day simple moving average (SMA) indicates a deviation of -10.1%, but today’s pre-market price action could hint at a shift.
Technical Landscape
The stock’s technical indicators reveal broader market challenges, with significant SMA calculations reflecting a decline over longer periods: -34.1% for the 50-day SMA and a staggering -97.2% for the 200-day SMA. However, with the recent price increase, traders may start to reevaluate their positions heading into the upcoming presentation.
Closing Thoughts
With the pre-market activity signaling renewed investor engagement, Profusa’s upcoming presentation at LINC 2026 is gathering attention as potential momentum for future trading sessions. As traders assess the implications of these developments, the stock’s performance may reflect broader market reactions as it approaches this key event.